{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:05:24Z","timestamp":1790301924807,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.peptides.2013.08.007","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T14:31:10Z","timestamp":1377095470000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Apelin and copeptin: Two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease"],"prefix":"10.1016","volume":"49","author":[{"given":"Antonio","family":"Lacquaniti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Chirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Lupica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Buemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Loddo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Caccamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Salis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullio","family":"Bertani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Buemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2013.08.007_bib0005","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.peptides.2013.08.007_bib0010","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1093\/ndt\/gfs070","article-title":"Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease","volume":"27","author":"Boertien","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.peptides.2013.08.007_bib0015","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.peptides.2013.08.007_bib0020","doi-asserted-by":"crossref","first-page":"10464","DOI":"10.1073\/pnas.0403518101","article-title":"Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release","volume":"101","author":"De Mota","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.peptides.2013.08.007_bib0025","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ki.1989.38","article-title":"The clinical utility of renal concentrating capacity in polycystic kidney disease","volume":"35","author":"Gabow","year":"1989","journal-title":"Kidney Int"},{"key":"10.1016\/j.peptides.2013.08.007_bib0030","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.peptides.2013.08.007_bib0035","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.peptides.2013.08.007_bib0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/ndt\/16.suppl_7.57","article-title":"Identification of patients and risk factors in chronic kidney disease evaluating risk factors and therapeutic strategies","volume":"16","author":"Levin","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.peptides.2013.08.007_bib0045","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1365-2826.2012.02316.x","article-title":"Apelin and vasopressin: two work better than one","volume":"24","author":"Llorens-Cortes","year":"2012","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.peptides.2013.08.007_bib0050","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.04560510","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease","volume":"6","author":"Meijer","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.peptides.2013.08.007_bib0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000326902","article-title":"Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease","volume":"34","author":"Meijer","year":"2011","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.peptides.2013.08.007_bib0060","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2215\/CJN.00360110","article-title":"Early renal abnormalities in autosomal dominant polycystic kidney disease","volume":"5","author":"Meijer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.peptides.2013.08.007_bib0065","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2013.08.007_bib0070","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1046\/j.1471-4159.2001.00320.x","article-title":"Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain","volume":"77","author":"Reaux","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.peptides.2013.08.007_bib0075","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1210\/en.2004-0384","article-title":"Dehydration-induced cross-regulation of apelin and vasopressin immunoreactivity levels in magnocellular hypothalamic neurons","volume":"145","author":"Reaux-Le Goazigo","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2013.08.007_bib0080","doi-asserted-by":"crossref","first-page":"e32533","DOI":"10.1371\/journal.pone.0032533","article-title":"Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study","volume":"7","author":"Ruggenenti","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.peptides.2013.08.007_bib0085","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1210\/jc.2007-0232","article-title":"Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects","volume":"92","author":"Szinnai","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.peptides.2013.08.007_bib0090","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.peptides.2013.08.007_bib0095","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.03250410","article-title":"Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease","volume":"6","author":"Torres","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.peptides.2013.08.007_bib0100","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on chronic kidney disease","volume":"39","author":"Work group and evidence review team membership","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.peptides.2013.08.007_bib0105","doi-asserted-by":"crossref","first-page":"12956","DOI":"10.1016\/S0021-9258(18)69255-5","article-title":"Regulation of vasopressin gene expression in rat hypothalamic neurons. Response to osmotic stimulation","volume":"261","author":"Zingg","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.peptides.2013.08.007_bib0110","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.11311111","article-title":"Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment","volume":"7","author":"Zittema","year":"2012","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978113002787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978113002787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T08:03:10Z","timestamp":1646380990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978113002787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":22,"alternative-id":["S0196978113002787"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2013.08.007","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apelin and copeptin: Two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2013.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}